2.0M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 510.00 per share. | 13 Mar 2025 | 3,231 | 23,281 (0%) | 0% | 510 | 1,647,810 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 500.00 per share. | 10 Mar 2025 | 3,298 | 51,671 (0%) | 0% | 500 | 1,649,000 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 500.00 per share. | 10 Mar 2025 | 3,231 | 26,512 (0%) | 0% | 500 | 1,615,500 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 499.99 per share. | 10 Mar 2025 | 3,242 | 51,239 (0%) | 0% | 500.0 | 1,620,968 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 485.49 per share. | 04 Mar 2025 | 4,058 | 54,481 (0%) | 0% | 485.5 | 1,970,118 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 490.00 per share. | 03 Mar 2025 | 3,231 | 29,743 (0%) | 0% | 490 | 1,583,190 | Common Stock |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 3,703 | 68,490 (0%) | 0% | 479.6 | 1,775,996 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 4,962 | 54,969 (0%) | 0% | 479.6 | 2,379,825 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 5,954 | 34,246 (0%) | 0% | 479.6 | 2,855,598 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 480.00 per share. | 26 Feb 2025 | 1,272 | 32,974 (0%) | 0% | 480 | 610,560 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 7,071 | 62,935 (0%) | 0% | 479.6 | 3,391,322 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 14,079 | 105,915 (0%) | 0% | 479.6 | 6,752,429 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 475.34 per share. | 26 Feb 2025 | 530 | 58,539 (0%) | 0% | 475.3 | 251,930 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 4,962 | 59,069 (0%) | 0% | 479.6 | 2,379,825 | Common Stock |
| Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 4,962 | 32,669 (0%) | 0% | 479.6 | 2,379,825 | Common Stock |
| Kristen C. Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 1,241 | 7,845 (0%) | 0% | 479.6 | 595,196 | Common Stock |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 2,470 | 72,193 (0%) | 0% | 483.3 | 1,193,702 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 3,310 | 59,931 (0%) | 0% | 483.3 | 1,599,657 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 480.95 per share. | 24 Feb 2025 | 848 | 40,200 (0%) | 0% | 481.0 | 407,846 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 3,971 | 41,048 (0%) | 0% | 483.3 | 1,919,105 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 4,716 | 70,006 (0%) | 0% | 483.3 | 2,279,148 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 9,386 | 119,994 (0%) | 0% | 483.3 | 4,536,066 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 3,310 | 64,385 (0%) | 0% | 483.3 | 1,599,657 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 480.95 per share. | 24 Feb 2025 | 354 | 64,031 (0%) | 0% | 480.9 | 170,256 | Common Stock |
| Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 3,310 | 37,631 (0%) | 0% | 483.3 | 1,599,657 | Common Stock |
| Kristen C. Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 828 | 9,970 (0%) | 0% | 483.3 | 400,156 | Common Stock |
| Kristen C. Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 480.95 per share. | 24 Feb 2025 | 884 | 9,086 (0%) | 0% | 481.0 | 425,160 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 480.00 per share. | 20 Feb 2025 | 1,111 | 45,019 (0%) | 0% | 480 | 533,280 | Common Stock |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 2,139 | 74,663 (0%) | 0% | 463.5 | 991,341 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 2,293 | 63,241 (0%) | 0% | 463.5 | 1,062,714 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 6,066 | 24,026 (0%) | 0% | 463.5 | 2,811,348 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 2,293 | 46,130 (0%) | 0% | 463.5 | 1,062,714 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 2,724 | 74,722 (0%) | 0% | 463.5 | 1,262,465 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 6,553 | 129,380 (0%) | 0% | 463.5 | 3,037,053 | Common Stock |
| Jonathan Biller | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 455.06 per share. | 14 Feb 2025 | 1,657 | 17,606 (0%) | 0% | 455.1 | 754,034 | Common Stock |
| Jonathan Biller | EVP and Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 1,504 | 19,263 (0%) | 0% | 463.5 | 697,044 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 2,293 | 67,939 (0%) | 0% | 463.5 | 1,062,714 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 455.06 per share. | 14 Feb 2025 | 244 | 67,695 (0%) | 0% | 455.1 | 111,035 | Common Stock |
| Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 1,912 | 40,941 (0%) | 0% | 463.5 | 886,136 | Common Stock |
| Kristen C. Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 564 | 11,469 (0%) | 0% | 463.5 | 261,391 | Common Stock |
| Kristen C. Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 455.06 per share. | 14 Feb 2025 | 671 | 10,798 (0%) | 0% | 455.1 | 305,345 | Common Stock |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,211 | 76,802 (0%) | 0% | 0 | Common Stock | |
| Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,655 | 65,534 (0%) | 0% | 0 | Common Stock | |
| Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 450.83 per share. | 12 Feb 2025 | 2,525 | 30,092 (0%) | 0% | 450.8 | 1,138,346 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,209 | 32,617 (0%) | 0% | 0 | Common Stock | |
| David Altshuler | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 5,324 | 48,423 (0%) | 0% | 0 | Common Stock | |
| Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,903 | 77,446 (0%) | 0% | 0 | Common Stock | |
| Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 19,015 | 135,933 (0%) | 0% | 0 | Common Stock | |
| Jonathan Biller | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 4,437 | 20,767 (0%) | 0% | 0 | Common Stock | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,211 | 70,232 (0%) | 0% | 0 | Common Stock | |
| Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 5,546 | 42,853 (0%) | 0% | 0 | Common Stock | |
| Kristen Ambrose C. | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 2,080 | 12,033 (0%) | 0% | 0 | Common Stock | |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 2,056 | 70,591 (0%) | 0% | 468.0 | 962,167 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 2,649 | 58,879 (0%) | 0% | 468.0 | 1,239,679 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 2,142 | 43,099 (0%) | 0% | 468.0 | 1,002,413 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 3,220 | 69,543 (0%) | 0% | 468.0 | 1,506,896 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 8,300 | 116,918 (0%) | 0% | 468.0 | 3,884,234 | Common Stock |
| Jonathan Biller | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 459.87 per share. | 10 Feb 2025 | 3,433 | 16,330 (0%) | 0% | 459.9 | 1,578,734 | Common Stock |
| Jonathan Biller | EVP and Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 1,632 | 19,763 (0%) | 0% | 468.0 | 763,743 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 459.83 per share. | 10 Feb 2025 | 310 | 64,021 (0%) | 0% | 459.8 | 142,547 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 2,143 | 64,331 (0%) | 0% | 468.0 | 1,002,881 | Common Stock |
| Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 2,142 | 37,307 (0%) | 0% | 468.0 | 1,002,413 | Common Stock |
| Kristen Ambrose C. | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 459.83 per share. | 10 Feb 2025 | 1,376 | 9,953 (0%) | 0% | 459.8 | 632,726 | Common Stock |
| Kristen Ambrose C. | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 591 | 11,329 (0%) | 0% | 468.0 | 276,576 | Common Stock |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 8,210 | 65,533 (0%) | 0% | 0 | Common Stock | |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 7,114 | 72,647 (0%) | 0% | 0 | Common Stock | |
| Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 7,114 | 61,528 (0%) | 0% | 0 | Common Stock | |
| Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 10,262 | 54,414 (0%) | 0% | 0 | Common Stock | |
| Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 15,414 | 25,408 (0%) | 0% | 0 | Common Stock | |
| David Altshuler | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 7,114 | 45,241 (0%) | 0% | 0 | Common Stock | |
| David Altshuler | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 12,314 | 38,127 (0%) | 0% | 0 | Common Stock | |
| Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 14,624 | 64,315 (0%) | 0% | 0 | Common Stock | |
| Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 8,448 | 72,763 (0%) | 0% | 0 | Common Stock | |
| Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 29,118 | 104,890 (0%) | 0% | 0 | Common Stock | |
| Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 20,328 | 125,218 (0%) | 0% | 0 | Common Stock | |
| Jonathan Biller | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 4,744 | 21,395 (0%) | 0% | 0 | Common Stock | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 10,262 | 59,360 (0%) | 0% | 0 | Common Stock | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 7,114 | 66,474 (0%) | 0% | 0 | Common Stock | |
| Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 5,928 | 39,449 (0%) | 0% | 0 | Common Stock | |
| Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 10,262 | 33,521 (0%) | 0% | 0 | Common Stock | |
| Kristen Ambrose C. | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 1,854 | 11,920 (0%) | 0% | 0 | Common Stock | |
| Kristen Ambrose C. | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 2,566 | 10,066 (0%) | 0% | 0 | Common Stock | |
| Bruce I. Sachs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 111 | 15,144 | - | - | Deferred Stock Units | |
| David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 478.53 per share. | 15 Nov 2024 | 15 | 25,813 (0%) | 0% | 478.5 | 7,178 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 518.27 per share. | 11 Nov 2024 | 3,000 | 44,137 (0%) | 0% | 518.3 | 1,554,810 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 515.00 per share. | 08 Nov 2024 | 15,198 | 75,772 (0%) | 0% | 515 | 7,826,970 | Common Stock |
| Bruce I. Sachs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2024 | 90 | 15,033 | - | - | Deferred Stock Units | |
| Jonathan Biller | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 461.66 per share. | 01 Oct 2024 | 999 | 16,651 (0%) | 0% | 461.7 | 461,198 | Common Stock |
| Jonathan Biller | EVP and Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 466.84 per share. | 01 Oct 2024 | 630 | 17,650 (0%) | 0% | 466.8 | 294,109 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 499.00 per share. | 30 Aug 2024 | 3,784 | 9,994 (0%) | 0% | 499 | 1,888,216 | Common Stock |
| Sangeeta N. Bhatia | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 152.74 per share. | 30 Aug 2024 | 646 | 5,081 (0%) | 0% | 152.7 | 98,670 | Common Stock |
| Sangeeta N. Bhatia | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 646 | 0 | - | - | Stock Option (Right to Buy) | |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 500.00 per share. | 30 Aug 2024 | 646 | 4,435 (0%) | 0% | 500 | 323,000 | Common Stock |
| Sangeeta N. Bhatia | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 1,292 | 646 | - | - | Stock Option (Right to Buy) | |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 466.29 per share. | 08 Aug 2024 | 1,292 | 4,435 (0%) | 0% | 466.3 | 602,447 | Common Stock |
| Sangeeta N. Bhatia | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 152.74 per share. | 08 Aug 2024 | 1,292 | 5,727 (0%) | 0% | 152.7 | 197,340 | Common Stock |
| Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 476.75 per share. | 07 Aug 2024 | 2,280 | 23,259 (0%) | 0% | 476.8 | 1,086,990 | Common Stock |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 5,295 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 508.00 per share. | 01 Aug 2024 | 5,295 | 40,000 (0%) | 0% | 508 | 2,689,860 | Common Stock |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.71 per share. | 01 Aug 2024 | 5,295 | 45,295 (0%) | 0% | 125.7 | 665,634 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 505.00 per share. | 30 Jul 2024 | 15,202 | 90,970 (0%) | 0% | 505 | 7,677,010 | Common Stock |
| Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 488.46 per share. | 24 Jul 2024 | 2,280 | 25,539 (0%) | 0% | 488.5 | 1,113,689 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 497.00 per share. | 22 Jul 2024 | 15,202 | 106,172 (0%) | 0% | 497 | 7,555,394 | Common Stock |
| Bruce I. Sachs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 89 | 14,943 | - | - | Deferred Stock Units | |
| Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 487.34 per share. | 10 Jul 2024 | 2,280 | 27,819 (0%) | 0% | 487.3 | 1,111,135 | Common Stock |
| Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 471.72 per share. | 26 Jun 2024 | 2,280 | 30,099 (0%) | 0% | 471.7 | 1,075,522 | Common Stock |
| Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 478.00 per share. | 12 Jun 2024 | 2,280 | 32,379 (0%) | 0% | 478 | 1,089,840 | Common Stock |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Jun 2024 | 4,600 | 0 (0%) | 0% | 0 | Common Stock | |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 460.00 per share. | 03 Jun 2024 | 3,250 | 47,137 (0%) | 0% | 460 | 1,495,000 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 460.00 per share. | 03 Jun 2024 | 2,175 | 49,098 (0%) | 0% | 460 | 1,000,500 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 439.11 per share. | 30 May 2024 | 2,350 | 53,523 (0%) | 0% | 439.1 | 1,031,909 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 445.00 per share. | 30 May 2024 | 2,250 | 51,273 (0%) | 0% | 445 | 1,001,250 | Common Stock |
| Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 445.56 per share. | 29 May 2024 | 2,280 | 34,659 (0%) | 0% | 445.6 | 1,015,877 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 454.79 per share. | 28 May 2024 | 3,250 | 50,387 (0%) | 0% | 454.8 | 1,478,068 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 24 May 2024 | 1,565 | 122,939 (0%) | 0% | 187.5 | 293,484 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2024 | 1,565 | 0 | - | - | Stock Option (Right to Buy) | |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 457.00 per share. | 24 May 2024 | 1,565 | 121,374 (0%) | 0% | 457 | 715,205 | Common Stock |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 7,073 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 448.00 per share. | 22 May 2024 | 7,073 | 40,000 (0%) | 0% | 448 | 3,168,704 | Common Stock |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 93.51 per share. | 22 May 2024 | 7,073 | 47,073 (0%) | 0% | 93.5 | 661,396 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 447.00 per share. | 20 May 2024 | 15,202 | 121,374 (0%) | 0% | 447 | 6,795,294 | Common Stock |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Sale of securities on an exchange or to another person at price $ 430.94 per share. | 15 May 2024 | 32 | 55,325 (0%) | 0% | 430.9 | 13,790 | Common Stock |
| David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 430.93 per share. | 15 May 2024 | 54 | 25,813 (0%) | 0% | 430.9 | 23,270 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 430.93 per share. | 15 May 2024 | 69 | 49,691 (0%) | 0% | 430.9 | 29,734 | Common Stock |
| Jennifer Schneider | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 922 | 922 (0%) | 0% | 0 | Common Stock | |
| Bruce I. Sachs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 3,142 | 3,142 | - | - | Stock Option (Right to Buy) | |
| Lloyd A. Carney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,001 | 6,319 (0%) | 0% | 0 | Common Stock | |
| Terrence C. Kearney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 3,142 | 3,142 | - | - | Stock Option (Right to Buy) | |
| Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 3,142 | 3,142 | - | - | Stock Option (Right to Buy) | |
| Suketu Upadhyay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,168 | 1,403 | - | - | Deferred Stock Units | |
| Suketu Upadhyay | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 May 2024 | 1,168 | 2,559 (0%) | 0% | - | Common Stock | |
| Suketu Upadhyay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,001 | 3,727 (0%) | 0% | 0 | Common Stock | |
| Michel Lagarde | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 3,142 | 3,142 | - | - | Stock Option (Right to Buy) | |
| Sangeeta N. Bhatia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,001 | 4,902 (0%) | 0% | 0 | Common Stock | |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 402.95 per share. | 01 May 2024 | 467 | 4,435 (0%) | 0% | 403.0 | 188,178 | Common Stock |
| Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,168 | 5,990 | - | - | Deferred Stock Units | |
| Diana L. McKenzie | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 May 2024 | 1,168 | 2,436 (0%) | 0% | - | Common Stock | |
| Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,001 | 3,604 (0%) | 0% | 0 | Common Stock | |
| Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 501 | 1,637 (0%) | 0% | 0 | Common Stock | |
| Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,571 | 1,571 | - | - | Stock Option (Right to Buy) | |
| Bruce I. Sachs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 109 | 14,853 | - | - | Deferred Stock Units | |
| Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 419.00 per share. | 01 Apr 2024 | 240 | 7,500 (0%) | 0% | 419 | 100,560 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 418.10 per share. | 01 Apr 2024 | 225 | 7,740 (0%) | 0% | 418.1 | 94,073 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 425.70 per share. | 23 Feb 2024 | 354 | 55,804 (0%) | 0% | 425.7 | 150,698 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 425.70 per share. | 23 Feb 2024 | 4,239 | 25,813 (0%) | 0% | 425.7 | 1,804,542 | Common Stock |
| A. Stuart Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 4,714 | 54,725 (0%) | 0% | 431.8 | 2,035,458 | Common Stock |
| Ambrose Kristen | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 425.70 per share. | 23 Feb 2024 | 883 | 7,965 (0%) | 0% | 425.7 | 375,893 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 828 | 8,848 (0%) | 0% | 431.8 | 357,522 | Common Stock |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Sale of securities on an exchange or to another person at price $ 425.70 per share. | 23 Feb 2024 | 3,004 | 55,325 (0%) | 0% | 425.7 | 1,278,803 | Common Stock |
| Arbuckle A. Stuart | EVP, COO | Sale of securities on an exchange or to another person at price $ 425.70 per share. | 23 Feb 2024 | 5,034 | 49,691 (0%) | 0% | 425.7 | 2,142,974 | Common Stock |
| K. Sachdev Amit | EVP Chief Patient & Ext Af Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 2,469 | 58,329 (0%) | 0% | 431.8 | 1,066,090 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 3,970 | 30,052 (0%) | 0% | 431.8 | 1,714,206 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 3,309 | 53,583 (0%) | 0% | 431.8 | 1,428,793 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 9,386 | 136,507 (0%) | 0% | 431.8 | 4,052,781 | Common Stock |
| Bozic Carmen | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 3,309 | 36,939 (0%) | 0% | 431.8 | 1,428,793 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 3,309 | 56,158 (0%) | 0% | 431.8 | 1,428,793 | Common Stock |
| A. Arbuckle Stuart | EVP, COO | Sale of securities on an exchange or to another person at price $ 421.77 per share. | 21 Feb 2024 | 3,603 | 59,439 (0%) | 0% | 421.8 | 1,519,637 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 421.77 per share. | 21 Feb 2024 | 360 | 59,467 (0%) | 0% | 421.8 | 151,837 | Common Stock |
| Amit Sachdev K. | EVP Chief Patient & Ext Af Off | Sale of securities on an exchange or to another person at price $ 421.77 per share. | 21 Feb 2024 | 3,191 | 60,798 (0%) | 0% | 421.8 | 1,345,868 | Common Stock |
| Altshuler David | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 421.77 per share. | 21 Feb 2024 | 3,002 | 34,022 (0%) | 0% | 421.8 | 1,266,154 | Common Stock |
| Jeffrey Leiden M | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 20 Feb 2024 | 4,118 | 13,778 (0%) | 0% | 420.6 | 1,731,948 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 9,359 | 152,912 (0%) | 0% | 424.0 | 3,968,310 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 3,750 | 59,704 (0%) | 0% | 424.0 | 1,590,038 | Common Stock |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 3,373 | 60,307 (0%) | 0% | 420.6 | 1,418,616 | Common Stock |
| Stuart Arbuckle A. | EVP, COO | Sale of securities on an exchange or to another person at price $ 420.79 per share. | 16 Feb 2024 | 4,804 | 63,042 (0%) | 0% | 420.8 | 2,021,475 | Common Stock |
| A. Arbuckle Stuart | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 3,373 | 67,846 (0%) | 0% | 420.6 | 1,418,616 | Common Stock |
| Kewalramani Reshma | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 7,019 | 145,893 (0%) | 0% | 420.6 | 2,952,051 | Common Stock |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 420.79 per share. | 16 Feb 2024 | 480 | 59,827 (0%) | 0% | 420.8 | 201,979 | Common Stock |
| F. Wagner Charles | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 2,812 | 56,892 (0%) | 0% | 420.6 | 1,182,671 | Common Stock |
| Bozic Carmen | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 3,750 | 43,060 (0%) | 0% | 424.0 | 1,590,038 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 420.79 per share. | 16 Feb 2024 | 4,002 | 37,024 (0%) | 0% | 420.8 | 1,684,002 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 2,812 | 41,026 (0%) | 0% | 420.6 | 1,182,671 | Common Stock |
| K. Amit Sachdev | EVP Chief Patient & Ext Af Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 3,498 | 70,866 (0%) | 0% | 424.0 | 1,483,187 | Common Stock |
| K. Amit Sachdev | EVP Chief Patient & Ext Af Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 2,623 | 68,243 (0%) | 0% | 420.6 | 1,103,181 | Common Stock |
| Arbuckle A. Stuart | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 4,499 | 71,219 (0%) | 0% | 424.0 | 1,907,621 | Common Stock |
| Amit Sachdev K. | EVP Chief Patient & Ext Af Off | Sale of securities on an exchange or to another person at price $ 420.79 per share. | 16 Feb 2024 | 4,254 | 63,989 (0%) | 0% | 420.8 | 1,790,041 | Common Stock |
| Altshuler David | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 3,750 | 43,838 (0%) | 0% | 424.0 | 1,590,038 | Common Stock |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 4,499 | 63,680 (0%) | 0% | 424.0 | 1,907,621 | Common Stock |
| Bozic Carmen | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 2,812 | 40,248 (0%) | 0% | 420.6 | 1,182,671 | Common Stock |
| M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.16 per share. | 14 Feb 2024 | 4,655 | 17,896 (0%) | 0% | 419.2 | 1,951,190 | Common Stock |
| M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.04 per share. | 14 Feb 2024 | 4,356 | 22,551 (0%) | 0% | 419.0 | 1,825,338 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.22 per share. | 12 Feb 2024 | 2,009 | 28,291 (0%) | 0% | 419.2 | 842,213 | Common Stock |
| Leiden Jeffrey M | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 420.39 per share. | 12 Feb 2024 | 647 | 27,644 (0%) | 0% | 420.4 | 271,992 | Common Stock |
| Leiden M Jeffrey | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.13 per share. | 12 Feb 2024 | 737 | 26,907 (0%) | 0% | 419.1 | 308,899 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 420.24 per share. | 09 Feb 2024 | 3,145 | 47,588 (0%) | 0% | 420.2 | 1,321,655 | Common Stock |
| Jonathan Biller | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 418.77 per share. | 09 Feb 2024 | 1,738 | 18,280 (0%) | 0% | 418.8 | 727,822 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 591 | 11,050 (0%) | 0% | 422.7 | 249,839 | Common Stock |
| Altshuler David | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 2,099 | 50,733 (0%) | 0% | 422.7 | 887,331 | Common Stock |
| Jonathan Biller | EVP and Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 1,588 | 20,018 (0%) | 0% | 422.7 | 671,311 | Common Stock |
| Arbuckle Stuart A. | EVP, COO | Sale of securities on an exchange or to another person at price $ 420.24 per share. | 09 Feb 2024 | 4,295 | 75,718 (0%) | 0% | 420.2 | 1,804,931 | Common Stock |
| Ambrose Kristen | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 420.24 per share. | 09 Feb 2024 | 1,374 | 9,676 (0%) | 0% | 420.2 | 577,410 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 420.24 per share. | 09 Feb 2024 | 314 | 68,179 (0%) | 0% | 420.2 | 131,955 | Common Stock |
| Charles Wagner F. | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 2,607 | 63,454 (0%) | 0% | 422.7 | 1,102,083 | Common Stock |
| K. Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale of securities on an exchange or to another person at price $ 420.24 per share. | 09 Feb 2024 | 3,222 | 74,364 (0%) | 0% | 420.2 | 1,354,013 | Common Stock |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 2,100 | 68,493 (0%) | 0% | 422.7 | 887,754 | Common Stock |
| K. Amit Sachdev | EVP Chief Patient & Ext Af Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 2,022 | 77,586 (0%) | 0% | 422.7 | 854,780 | Common Stock |
| Bozic Carmen | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 2,100 | 46,810 (0%) | 0% | 422.7 | 887,754 | Common Stock |
| A. Arbuckle Stuart | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 3,177 | 80,013 (0%) | 0% | 422.7 | 1,343,045 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 8,255 | 162,271 (0%) | 0% | 422.7 | 3,489,719 | Common Stock |
| Leiden M Jeffrey | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 08 Feb 2024 | 8,048 | 30,300 (0%) | 0% | 422.7 | 3,402,212 | Common Stock |
| Leiden M Jeffrey | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 421.73 per share. | 08 Feb 2024 | 2,698 | 38,348 (0%) | 0% | 421.7 | 1,137,828 | Common Stock |
| Ambrose Kristen | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 2,950 | 9,788 (0%) | 0% | 0 | Common Stock | |
| David Altshuler | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,866 | 45,718 (0%) | 0% | 0 | Common Stock | |
| A. Stuart Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 11,210 | 74,742 (0%) | 0% | 0 | Common Stock | |
| Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,928 | 48,910 (0%) | 0% | 0 | Common Stock | |
| Sachdev Amit K. | EVP Chief Patient & Ext Af Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,866 | 72,494 (0%) | 0% | 0 | Common Stock | |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,114 | 70,593 (0%) | 0% | 0 | Common Stock | |
| Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 26,972 | 150,199 (0%) | 0% | 0 | Common Stock | |
| Kewalramani Reshma | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 20,327 | 170,526 (0%) | 0% | 0 | Common Stock | |
| Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 9,440 | 58,947 (0%) | 0% | 0 | Common Stock | |
| Arbuckle A. Stuart | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 8,448 | 83,190 (0%) | 0% | 0 | Common Stock | |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,866 | 63,479 (0%) | 0% | 0 | Common Stock | |
| Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,814 | 35,116 (0%) | 0% | 0 | Common Stock | |
| Arbuckle A. Stuart | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 6,976 | 63,532 (0%) | 0% | 0 | Common Stock | |
| Bozic Carmen | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,866 | 42,982 (0%) | 0% | 0 | Common Stock | |
| Amit K. Sachdev | EVP Chief Patient & Ext Af Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,814 | 64,628 (0%) | 0% | 0 | Common Stock | |
| Jeffrey Leiden M | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 20,452 | 33,339 (0%) | 0% | 0 | Common Stock | |
| F. Wagner Charles | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,814 | 49,507 (0%) | 0% | 0 | Common Stock | |
| Sachdev K. Amit | EVP Chief Patient & Ext Af Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,114 | 79,608 (0%) | 0% | 0 | Common Stock | |
| M Jeffrey Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 10,464 | 12,887 (0%) | 0% | 0 | Common Stock | |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 6,976 | 55,613 (0%) | 0% | 0 | Common Stock | |
| M Jeffrey Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,707 | 41,046 (0%) | 0% | 0 | Common Stock | |
| Wagner F. Charles | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,114 | 66,061 (0%) | 0% | 0 | Common Stock | |
| Kewalramani Reshma | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 14,516 | 123,227 (0%) | 0% | 0 | Common Stock | |
| Altshuler David | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,114 | 52,832 (0%) | 0% | 0 | Common Stock | |
| Biller Jonathan | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 6,294 | 16,863 (0%) | 0% | 0 | Common Stock | |
| Ambrose Kristen | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 1,853 | 11,641 (0%) | 0% | 0 | Common Stock | |
| Altshuler David | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,814 | 37,852 (0%) | 0% | 0 | Common Stock | |
| Biller Jonathan | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 4,743 | 21,606 (0%) | 0% | 0 | Common Stock | |
| L. McKenzie Diana | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 76 | 4,822 | - | - | Deferred Stock Units | |
| Sachs Bruce I. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 101 | 14,744 | - | - | Deferred Stock Units | |
| M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.07 per share. | 08 Jan 2024 | 6,648 | 2,423 (0%) | 0% | 419.1 | 2,785,977 | Common Stock |
| Wagner Charles F. | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 405.00 per share. | 02 Jan 2024 | 3,000 | 43,693 (0%) | 0% | 405 | 1,215,000 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 14,077 | 1,565 | - | - | Stock Option (Right to Buy) | |
| Kewalramani Reshma | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 15 Dec 2023 | 14,077 | 125,846 (0%) | 0% | 187.5 | 2,639,860 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 3,058 | 0 | - | - | Stock Option (Right to Buy) | |
| Kewalramani Reshma | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 407.00 per share. | 15 Dec 2023 | 17,135 | 108,711 (0%) | 0% | 407 | 6,973,945 | Common Stock |
| Kewalramani Reshma | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.57 per share. | 15 Dec 2023 | 3,058 | 111,769 (0%) | 0% | 155.6 | 475,733 | Common Stock |
| Stuart Arbuckle A. | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2023 | 8,603 | 0 | - | - | Stock Option (Right to Buy) | |
| Leiden Jeffrey M | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 399.41 per share. | 13 Dec 2023 | 13,254 | 9,171 (0%) | 0% | 399.4 | 5,293,780 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 399.00 per share. | 13 Dec 2023 | 8,603 | 56,556 (0%) | 0% | 399 | 3,432,597 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 397.00 per share. | 13 Dec 2023 | 5,098 | 108,711 (0%) | 0% | 397 | 2,023,906 | Common Stock |
| Leiden M Jeffrey | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 400.19 per share. | 13 Dec 2023 | 100 | 9,071 (0%) | 0% | 400.2 | 40,019 | Common Stock |
| Arbuckle A. Stuart | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 13 Dec 2023 | 8,603 | 65,159 (0%) | 0% | 187.5 | 1,613,321 | Common Stock |
| Thornberry Nancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 1,136 | 1,136 (0%) | 0% | 0 | Common Stock | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 355.00 per share. | 23 Aug 2023 | 2,500 | 48,637 (0%) | 0% | 355 | 887,500 | Common Stock |
| Amit K. Sachdev | EVP, Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 10 Aug 2023 | 10,031 | 58,814 (0%) | 0% | 350 | 3,510,850 | Common Stock |
| Terrence C. Kearney | Director | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 10 Aug 2023 | 10,000 | 6,536 (0%) | 0% | 350 | 3,500,000 | Common Stock |
| Terrence C. Kearney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 127.54 per share. | 10 Aug 2023 | 10,000 | 16,536 (0%) | 0% | 127.5 | 1,275,400 | Common Stock |
| Terrence C. Kearney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 345.79 per share. | 10 Aug 2023 | 5,750 | 51,137 (0%) | 0% | 345.8 | 1,988,293 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 345.51 per share. | 09 Aug 2023 | 63 | 32,038 (0%) | 0% | 345.5 | 21,767 | Common Stock |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 345.51 per share. | 09 Aug 2023 | 242 | 4,386 (0%) | 0% | 345.5 | 83,613 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 355.00 per share. | 17 Jul 2023 | 7,828 | 118,906 (0%) | 0% | 355 | 2,778,940 | Common Stock |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 357.29 per share. | 14 Jul 2023 | 3,842 | 40,000 (0%) | 0% | 357.3 | 1,372,708 | Common Stock |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 11,250 | 11,250 | - | - | Stock Option (Right to Buy) | |
| Bruce I. Sachs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 124 | 14,524 | - | - | Deferred Stock Units | |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 127.54 per share. | 14 Jul 2023 | 11,250 | 51,250 (0%) | 0% | 127.5 | 1,434,825 | Common Stock |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 356.75 per share. | 14 Jul 2023 | 5,711 | 43,842 (0%) | 0% | 356.7 | 2,037,399 | Common Stock |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 355.54 per share. | 14 Jul 2023 | 1,697 | 49,553 (0%) | 0% | 355.5 | 603,351 | Common Stock |
| Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 89 | 4,656 | - | - | Deferred Stock Units | |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 349.00 per share. | 15 Jun 2023 | 8,603 | 56,556 (0%) | 0% | 349 | 3,002,447 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 8,603 | 8,603 | - | - | Stock Option (Right to Buy) | |
| Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 15 Jun 2023 | 8,603 | 65,159 (0%) | 0% | 187.5 | 1,613,321 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 329.82 per share. | 30 May 2023 | 82 | 56,556 (0%) | 0% | 329.8 | 27,045 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 329.82 per share. | 30 May 2023 | 289 | 6,838 (0%) | 0% | 329.8 | 95,318 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.30 per share. | 05 May 2023 | 171 | 36,512 (0%) | 0% | 350.3 | 59,901 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.00 per share. | 05 May 2023 | 1,125 | 35,387 (0%) | 0% | 349 | 392,625 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.38 per share. | 05 May 2023 | 708 | 36,683 (0%) | 0% | 349.4 | 247,361 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 05 May 2023 | 2,850 | 32,038 (0%) | 0% | 350 | 997,500 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 350.03 per share. | 05 May 2023 | 422 | 34,888 (0%) | 0% | 350.0 | 147,713 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.53 per share. | 02 May 2023 | 1,800 | 38,091 (0%) | 0% | 350.5 | 630,954 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.22 per share. | 02 May 2023 | 2,008 | 39,891 (0%) | 0% | 349.2 | 701,234 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 353.18 per share. | 02 May 2023 | 300 | 41,899 (0%) | 0% | 353.2 | 105,954 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.48 per share. | 02 May 2023 | 1,505 | 42,199 (0%) | 0% | 350.5 | 527,472 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.48 per share. | 02 May 2023 | 4,645 | 43,704 (0%) | 0% | 349.5 | 1,623,335 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 351.59 per share. | 02 May 2023 | 700 | 37,391 (0%) | 0% | 351.6 | 246,113 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 350.32 per share. | 02 May 2023 | 1,411 | 38,302 (0%) | 0% | 350.3 | 494,302 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 351.60 per share. | 02 May 2023 | 728 | 35,310 (0%) | 0% | 351.6 | 255,965 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 350.44 per share. | 02 May 2023 | 2,053 | 36,038 (0%) | 0% | 350.4 | 719,453 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 353.24 per share. | 02 May 2023 | 169 | 38,091 (0%) | 0% | 353.2 | 59,698 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 351.64 per share. | 02 May 2023 | 42 | 38,260 (0%) | 0% | 351.6 | 14,769 | Common Stock |
| Bruce I. Sachs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 3,481 | 3,481 | - | - | Stock Option (Right to Buy) | |
| Lloyd A. Carney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,168 | 5,318 (0%) | 0% | 0 | Common Stock | |
| Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 3,481 | 3,481 | - | - | Stock Option (Right to Buy) | |
| Terrence C. Kearney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 3,481 | 3,481 | - | - | Stock Option (Right to Buy) | |
| Yuchun Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 3,481 | 3,481 | - | - | Stock Option (Right to Buy) | |
| Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 584 | 6,474 (0%) | 0% | 0 | Common Stock | |
| Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,741 | 1,741 | - | - | Stock Option (Right to Buy) | |
| Suketu Upadhyay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,168 | 2,726 (0%) | 0% | 0 | Common Stock | |
| Sangeeta N. Bhatia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,168 | 5,208 (0%) | 0% | 0 | Common Stock | |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 349.82 per share. | 01 May 2023 | 163 | 4,691 (0%) | 0% | 349.8 | 57,021 | Common Stock |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 348.16 per share. | 01 May 2023 | 120 | 4,854 (0%) | 0% | 348.2 | 41,779 | Common Stock |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 346.69 per share. | 01 May 2023 | 172 | 4,974 (0%) | 0% | 346.7 | 59,631 | Common Stock |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 345.94 per share. | 01 May 2023 | 62 | 5,146 (0%) | 0% | 345.9 | 21,448 | Common Stock |
| Sangeeta N. Bhatia | Director | Sale of securities on an exchange or to another person at price $ 351.21 per share. | 01 May 2023 | 63 | 4,628 (0%) | 0% | 351.2 | 22,126 | Common Stock |
| Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,168 | 2,603 (0%) | 0% | 0 | Common Stock | |
| Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,449 | 4,566 | - | - | Deferred Stock Units | |
| Diana L. McKenzie | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 May 2023 | 1,449 | 1,435 (0%) | 0% | - | Common Stock | |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 339.43 per share. | 27 Apr 2023 | 1,668 | 126,690 (0%) | 0% | 339.4 | 566,169 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 340.18 per share. | 27 Apr 2023 | 38 | 126,652 (0%) | 0% | 340.2 | 12,927 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 338.69 per share. | 27 Apr 2023 | 1,611 | 128,358 (0%) | 0% | 338.7 | 545,630 | Common Stock |
| Bruce I. Sachs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 131 | 14,400 | - | - | Deferred Stock Units | |
| Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 90 | 3,117 | - | - | Deferred Stock Units | |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 325.65 per share. | 12 Apr 2023 | 2,917 | 59,593 (0%) | 0% | 325.6 | 949,921 | Common Stock |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2023 | 21,300 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce I. Sachs | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Apr 2023 | 1,210 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 327.48 per share. | 12 Apr 2023 | 8,026 | 41,210 (0%) | 0% | 327.5 | 2,628,354 | Common Stock |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 326.46 per share. | 12 Apr 2023 | 10,357 | 49,236 (0%) | 0% | 326.5 | 3,381,146 | Common Stock |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.14 per share. | 12 Apr 2023 | 21,300 | 62,510 (0%) | 0% | 72.1 | 1,536,582 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 327.43 per share. | 12 Apr 2023 | 2,625 | 39,713 (0%) | 0% | 327.4 | 859,504 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 326.45 per share. | 12 Apr 2023 | 4,068 | 42,338 (0%) | 0% | 326.5 | 1,327,999 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 325.70 per share. | 12 Apr 2023 | 874 | 46,406 (0%) | 0% | 325.7 | 284,662 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 314.22 per share. | 04 Apr 2023 | 211 | 47,591 (0%) | 0% | 314.2 | 66,300 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 318.68 per share. | 04 Apr 2023 | 31 | 47,280 (0%) | 0% | 318.7 | 9,879 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 317.65 per share. | 04 Apr 2023 | 96 | 47,311 (0%) | 0% | 317.6 | 30,494 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 316.76 per share. | 04 Apr 2023 | 90 | 47,407 (0%) | 0% | 316.8 | 28,508 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 315.66 per share. | 04 Apr 2023 | 94 | 47,497 (0%) | 0% | 315.7 | 29,672 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Payment of exercise price or tax liability using portion of securities received from the company at price $ 313.74 per share. | 31 Mar 2023 | 1,466 | 47,802 (0%) | 0% | 313.7 | 459,943 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 313.74 per share. | 31 Mar 2023 | 176 | 7,127 (0%) | 0% | 313.7 | 55,218 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 305.38 per share. | 24 Mar 2023 | 1,768 | 49,611 (0%) | 0% | 305.4 | 539,912 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 295.43 per share. | 17 Mar 2023 | 784 | 52,235 (0%) | 0% | 295.4 | 231,617 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 301.12 per share. | 17 Mar 2023 | 16 | 51,379 (0%) | 0% | 301.1 | 4,818 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 299.58 per share. | 17 Mar 2023 | 240 | 51,395 (0%) | 0% | 299.6 | 71,899 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 298.09 per share. | 17 Mar 2023 | 360 | 51,635 (0%) | 0% | 298.1 | 107,312 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 296.30 per share. | 17 Mar 2023 | 240 | 51,995 (0%) | 0% | 296.3 | 71,112 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 294.52 per share. | 17 Mar 2023 | 360 | 53,019 (0%) | 0% | 294.5 | 106,027 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 301.07 per share. | 16 Mar 2023 | 264 | 49,268 (0%) | 0% | 301.1 | 79,482 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 300.54 per share. | 16 Mar 2023 | 2,482 | 49,532 (0%) | 0% | 300.5 | 745,940 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 287.83 per share. | 10 Mar 2023 | 515 | 57,257 (0%) | 0% | 287.8 | 148,232 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 296.77 per share. | 10 Mar 2023 | 62 | 53,379 (0%) | 0% | 296.8 | 18,400 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 295.89 per share. | 10 Mar 2023 | 292 | 53,441 (0%) | 0% | 295.9 | 86,400 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 294.52 per share. | 10 Mar 2023 | 715 | 53,733 (0%) | 0% | 294.5 | 210,582 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 293.35 per share. | 10 Mar 2023 | 1,153 | 54,448 (0%) | 0% | 293.4 | 338,233 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 292.41 per share. | 10 Mar 2023 | 420 | 55,061 (0%) | 0% | 292.4 | 122,812 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 288.29 per share. | 10 Mar 2023 | 24 | 56,021 (0%) | 0% | 288.3 | 6,919 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 294.94 per share. | 10 Mar 2023 | 102 | 56,045 (0%) | 0% | 294.9 | 30,084 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 293.59 per share. | 10 Mar 2023 | 27 | 56,147 (0%) | 0% | 293.6 | 7,927 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 292.68 per share. | 10 Mar 2023 | 185 | 56,174 (0%) | 0% | 292.7 | 54,146 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 291.47 per share. | 10 Mar 2023 | 541 | 56,359 (0%) | 0% | 291.5 | 157,685 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 289.43 per share. | 10 Mar 2023 | 30 | 56,900 (0%) | 0% | 289.4 | 8,683 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 288.91 per share. | 10 Mar 2023 | 327 | 56,930 (0%) | 0% | 288.9 | 94,474 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 286.64 per share. | 10 Mar 2023 | 361 | 57,772 (0%) | 0% | 286.6 | 103,477 | Common Stock |
| Amit K. Sachdev | EVP, Chief Patient Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 2,468 | 66,518 (0%) | 0% | 289.1 | 713,548 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 3,308 | 58,133 (0%) | 0% | 289.1 | 956,409 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 13,730 | 48,349 (0%) | 0% | 289.1 | 3,969,618 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 288.74 per share. | 24 Feb 2023 | 300 | 32,340 (0%) | 0% | 288.7 | 86,622 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 287.23 per share. | 24 Feb 2023 | 3,636 | 32,640 (0%) | 0% | 287.2 | 1,044,368 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 289.60 per share. | 24 Feb 2023 | 302 | 32,038 (0%) | 0% | 289.6 | 87,459 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 3,970 | 36,276 (0%) | 0% | 289.1 | 1,147,806 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 4,714 | 61,590 (0%) | 0% | 289.1 | 1,362,912 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 288.92 per share. | 24 Feb 2023 | 800 | 56,556 (0%) | 0% | 288.9 | 231,136 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 287.59 per share. | 24 Feb 2023 | 400 | 57,356 (0%) | 0% | 287.6 | 115,036 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 287.16 per share. | 24 Feb 2023 | 3,834 | 57,756 (0%) | 0% | 287.2 | 1,100,971 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 9,386 | 129,969 (0%) | 0% | 289.1 | 2,713,680 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 3,970 | 52,014 (0%) | 0% | 289.1 | 1,147,806 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 288.33 per share. | 24 Feb 2023 | 51 | 56,825 (0%) | 0% | 288.3 | 14,705 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 289.30 per share. | 24 Feb 2023 | 20 | 56,805 (0%) | 0% | 289.3 | 5,786 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 287.20 per share. | 24 Feb 2023 | 283 | 56,876 (0%) | 0% | 287.2 | 81,278 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 3,308 | 57,159 (0%) | 0% | 289.1 | 956,409 | Common Stock |
| Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 3,308 | 63,207 (0%) | 0% | 289.1 | 956,409 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 288.68 per share. | 24 Feb 2023 | 183 | 7,345 (0%) | 0% | 288.7 | 52,828 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 502 | 8,510 (0%) | 0% | 289.1 | 145,138 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 289.62 per share. | 24 Feb 2023 | 42 | 7,303 (0%) | 0% | 289.6 | 12,164 | Common Stock |
| Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 287.25 per share. | 24 Feb 2023 | 982 | 7,528 (0%) | 0% | 287.3 | 282,080 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 291.84 per share. | 22 Feb 2023 | 129 | 68,576 (0%) | 0% | 291.8 | 37,647 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 296.31 per share. | 22 Feb 2023 | 200 | 66,304 (0%) | 0% | 296.3 | 59,262 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 295.38 per share. | 22 Feb 2023 | 394 | 66,504 (0%) | 0% | 295.4 | 116,380 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 294.29 per share. | 22 Feb 2023 | 1,378 | 66,898 (0%) | 0% | 294.3 | 405,532 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 292.86 per share. | 22 Feb 2023 | 300 | 68,276 (0%) | 0% | 292.9 | 87,858 | Common Stock |
| Amit K. Sachdev | EVP, Chief Patient Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 3,498 | 68,986 (0%) | 0% | 292.8 | 1,024,389 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 3,750 | 61,441 (0%) | 0% | 292.9 | 1,098,188 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 3,750 | 44,248 (0%) | 0% | 292.9 | 1,098,188 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 291.00 per share. | 17 Feb 2023 | 36 | 44,212 (0%) | 0% | 291 | 10,476 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 292.76 per share. | 17 Feb 2023 | 1,223 | 42,989 (0%) | 0% | 292.8 | 358,045 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 294.03 per share. | 17 Feb 2023 | 1,843 | 41,146 (0%) | 0% | 294.0 | 541,897 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 294.73 per share. | 17 Feb 2023 | 900 | 40,246 (0%) | 0% | 294.7 | 265,257 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 294.58 per share. | 17 Feb 2023 | 736 | 68,705 (0%) | 0% | 294.6 | 216,811 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 4,498 | 71,107 (0%) | 0% | 292.8 | 1,317,239 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 291.00 per share. | 17 Feb 2023 | 21 | 71,086 (0%) | 0% | 291 | 6,111 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 292.77 per share. | 17 Feb 2023 | 545 | 70,541 (0%) | 0% | 292.8 | 159,560 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 293.74 per share. | 17 Feb 2023 | 1,100 | 69,441 (0%) | 0% | 293.7 | 323,114 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 9,359 | 139,355 (0%) | 0% | 292.8 | 2,740,783 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 3,750 | 55,984 (0%) | 0% | 292.9 | 1,098,188 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 293.83 per share. | 17 Feb 2023 | 207 | 60,591 (0%) | 0% | 293.8 | 60,823 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 292.85 per share. | 17 Feb 2023 | 145 | 60,798 (0%) | 0% | 292.8 | 42,463 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 4,498 | 60,947 (0%) | 0% | 292.8 | 1,317,239 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 294.77 per share. | 17 Feb 2023 | 124 | 60,467 (0%) | 0% | 294.8 | 36,551 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 291.00 per share. | 17 Feb 2023 | 4 | 60,943 (0%) | 0% | 291 | 1,164 | Common Stock |
| Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 3,750 | 66,515 (0%) | 0% | 292.9 | 1,098,188 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 296.85 per share. | 14 Feb 2023 | 842 | 52,754 (0%) | 0% | 296.9 | 249,948 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 301.02 per share. | 14 Feb 2023 | 308 | 47,998 (0%) | 0% | 301.0 | 92,714 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 300.11 per share. | 14 Feb 2023 | 1,888 | 48,306 (0%) | 0% | 300.1 | 566,608 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 299.08 per share. | 14 Feb 2023 | 2,165 | 50,194 (0%) | 0% | 299.1 | 647,508 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 297.97 per share. | 14 Feb 2023 | 395 | 52,359 (0%) | 0% | 298.0 | 117,698 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 295.79 per share. | 14 Feb 2023 | 800 | 53,596 (0%) | 0% | 295.8 | 236,632 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 295.84 per share. | 14 Feb 2023 | 800 | 81,203 (0%) | 0% | 295.8 | 236,672 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 299.13 per share. | 14 Feb 2023 | 2,003 | 77,739 (0%) | 0% | 299.1 | 599,157 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 298.14 per share. | 14 Feb 2023 | 560 | 79,742 (0%) | 0% | 298.1 | 166,958 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 296.85 per share. | 14 Feb 2023 | 901 | 80,302 (0%) | 0% | 296.9 | 267,462 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.09 per share. | 14 Feb 2023 | 1,734 | 76,005 (0%) | 0% | 300.1 | 520,356 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.89 per share. | 14 Feb 2023 | 400 | 75,605 (0%) | 0% | 300.9 | 120,356 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 300.29 per share. | 14 Feb 2023 | 1,902 | 60,013 (0%) | 0% | 300.3 | 571,152 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 301.11 per share. | 14 Feb 2023 | 279 | 59,734 (0%) | 0% | 301.1 | 84,010 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 295.89 per share. | 14 Feb 2023 | 71 | 65,694 (0%) | 0% | 295.9 | 21,008 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 296.50 per share. | 14 Feb 2023 | 20 | 65,674 (0%) | 0% | 296.5 | 5,930 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 297.98 per share. | 14 Feb 2023 | 43 | 65,631 (0%) | 0% | 298.0 | 12,813 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 299.60 per share. | 14 Feb 2023 | 135 | 65,496 (0%) | 0% | 299.6 | 40,446 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 300.59 per share. | 14 Feb 2023 | 51 | 65,445 (0%) | 0% | 300.6 | 15,330 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 13 Feb 2023 | 13,344 | 62,079 (0%) | 0% | 298.3 | 3,979,981 | Common Stock |
| Amit K. Sachdev | EVP, Chief Patient Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 4,657 | 72,484 (0%) | 0% | 298.3 | 1,388,997 | Common Stock |
| Amit K. Sachdev | EVP, Chief Patient Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 2,611 | 77,141 (0%) | 0% | 294.3 | 768,496 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 4,992 | 65,191 (0%) | 0% | 298.3 | 1,488,914 | Common Stock |
| Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 2,707 | 70,183 (0%) | 0% | 294.3 | 796,751 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 3,461 | 65,184 (0%) | 0% | 294.3 | 1,018,676 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 5,990 | 59,194 (0%) | 0% | 298.3 | 1,786,577 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 296.44 per share. | 10 Feb 2023 | 245 | 58,949 (0%) | 0% | 296.4 | 72,628 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 298.47 per share. | 10 Feb 2023 | 2,160 | 56,789 (0%) | 0% | 298.5 | 644,695 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 299.36 per share. | 10 Feb 2023 | 1,893 | 54,896 (0%) | 0% | 299.4 | 566,688 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 300.23 per share. | 10 Feb 2023 | 500 | 54,396 (0%) | 0% | 300.2 | 150,115 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 5,990 | 86,890 (0%) | 0% | 298.3 | 1,786,577 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.13 per share. | 10 Feb 2023 | 835 | 82,003 (0%) | 0% | 300.1 | 250,609 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 299.26 per share. | 10 Feb 2023 | 1,779 | 82,838 (0%) | 0% | 299.3 | 532,384 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 298.42 per share. | 10 Feb 2023 | 2,028 | 84,617 (0%) | 0% | 298.4 | 605,196 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 296.44 per share. | 10 Feb 2023 | 245 | 86,645 (0%) | 0% | 296.4 | 72,628 | Common Stock |
| Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 3,372 | 92,880 (0%) | 0% | 294.3 | 992,481 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 5,990 | 148,714 (0%) | 0% | 298.3 | 1,786,577 | Common Stock |
| Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 3,372 | 154,704 (0%) | 0% | 294.3 | 992,481 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 902 | 66,368 (0%) | 0% | 294.3 | 265,486 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 300.39 per share. | 10 Feb 2023 | 113 | 61,915 (0%) | 0% | 300.4 | 33,944 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 4,340 | 62,028 (0%) | 0% | 298.3 | 1,294,448 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 298.12 per share. | 10 Feb 2023 | 78 | 65,960 (0%) | 0% | 298.1 | 23,253 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 299.88 per share. | 10 Feb 2023 | 64 | 65,776 (0%) | 0% | 299.9 | 19,192 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 298.98 per share. | 10 Feb 2023 | 120 | 65,840 (0%) | 0% | 299.0 | 35,878 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 300.82 per share. | 10 Feb 2023 | 11 | 65,765 (0%) | 0% | 300.8 | 3,309 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 2,995 | 66,040 (0%) | 0% | 298.3 | 893,289 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 1,377 | 69,035 (0%) | 0% | 294.3 | 405,292 | Common Stock |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale of securities on an exchange or to another person at price $ 296.00 per share. | 10 Feb 2023 | 2 | 66,038 (0%) | 0% | 296 | 592 | Common Stock |
| Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 2,707 | 75,257 (0%) | 0% | 294.3 | 796,751 | Common Stock |
| Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 4,992 | 70,265 (0%) | 0% | 298.3 | 1,488,914 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 06 Feb 2023 | 1,304 | 69,949 (0%) | 0% | 187.5 | 244,539 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 1,304 | 0 | - | - | Stock Option (Right to Buy) | |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 309.06 per share. | 06 Feb 2023 | 153 | 68,645 (0%) | 0% | 309.1 | 47,286 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 306.70 per share. | 06 Feb 2023 | 620 | 68,798 (0%) | 0% | 306.7 | 190,154 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 305.08 per share. | 06 Feb 2023 | 349 | 69,418 (0%) | 0% | 305.1 | 106,473 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 303.64 per share. | 06 Feb 2023 | 100 | 69,767 (0%) | 0% | 303.6 | 30,364 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 302.00 per share. | 06 Feb 2023 | 70 | 69,867 (0%) | 0% | 302 | 21,140 | Common Stock |
| David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 300.42 per share. | 06 Feb 2023 | 12 | 69,937 (0%) | 0% | 300.4 | 3,605 | Common Stock |
| Amit K. Sachdev | EVP, Chief Patient Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Feb 2023 | 1,672 | 11,052 (0%) | 0% | 0 | Common Stock | |
| Amit K. Sachdev | EVP, Chief Patient Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,324 | 63,676 (0%) | 0% | 0 | Common Stock | |
| Amit K. Sachdev | EVP, Chief Patient Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 8,210 | 71,886 (0%) | 0% | 0 | Common Stock | |
| Amit K. Sachdev | EVP, Chief Patient Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 7,866 | 79,752 (0%) | 0% | 0 | Common Stock | |
| Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,324 | 53,188 (0%) | 0% | 0 | Common Stock | |
| Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 9,440 | 72,890 (0%) | 0% | 0 | Common Stock | |
| Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,262 | 63,450 (0%) | 0% | 0 | Common Stock | |
| Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 31,462 | 33,885 (0%) | 0% | 0 | Common Stock | |
| Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 34,890 | 68,775 (0%) | 0% | 0 | Common Stock | |
| Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 317.83 per share. | 01 Feb 2023 | 3,578 | 75,423 (0%) | 0% | 317.8 | 1,137,196 | Common Stock |
| Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,226 | 79,001 (0%) | 0% | 0 | Common Stock | |
| David Altshuler | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 7,866 | 68,645 (0%) | 0% | 0 | Common Stock | |
| David Altshuler | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,314 | 60,779 (0%) | 0% | 0 | Common Stock | |
| David Altshuler | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,388 | 48,465 (0%) | 0% | 0 | Common Stock | |
| Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 14,624 | 85,043 (0%) | 0% | 0 | Common Stock | |
| Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,388 | 70,419 (0%) | 0% | 0 | Common Stock | |
| Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 11,209 | 96,252 (0%) | 0% | 0 | Common Stock | |
| Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,388 | 101,986 (0%) | 0% | 0 | Common Stock | |
| Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 26,972 | 158,076 (0%) | 0% | 0 | Common Stock | |
| Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 29,118 | 131,104 (0%) | 0% | 0 | Common Stock | |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,314 | 59,404 (0%) | 0% | 0 | Common Stock | |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 7,866 | 67,270 (0%) | 0% | 0 | Common Stock | |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 9,092 | 47,090 (0%) | 0% | 0 | Common Stock | |
| Jonathan Biller | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 6,293 | 11,587 (0%) | 0% | 0 | Common Stock | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 7,866 | 70,412 (0%) | 0% | 0 | Common Stock | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 6,194 | 52,284 (0%) | 0% | 0 | Common Stock | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,262 | 62,546 (0%) | 0% | 0 | Common Stock | |
| Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,262 | 70,098 (0%) | 0% | 0 | Common Stock | |
| Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 7,866 | 77,964 (0%) | 0% | 0 | Common Stock | |
| Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,324 | 59,836 (0%) | 0% | 0 | Common Stock | |
| Kristen Ambrose | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 2,950 | 9,012 (0%) | 0% | 0 | Common Stock | |
| Kristen Ambrose | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 2,566 | 6,062 (0%) | 0% | 0 | Common Stock | |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.14 per share. | 31 Jan 2023 | 1,200 | 42,410 (0%) | 0% | 72.1 | 86,568 | Common Stock |
| Bruce I. Sachs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 1,200 | 21,300 | - | - | Stock Option (Right to Buy) | |
| Bruce I. Sachs | Director | Sale of securities on an exchange or to another person at price $ 325.01 per share. | 31 Jan 2023 | 1,200 | 41,210 (0%) | 0% | 325.0 | 390,012 | Common Stock |
| Bastiano Sanna | EVP, Cell & Genetic Therapies | Sale of securities on an exchange or to another person at price $ 325.00 per share. | 31 Jan 2023 | 106 | 37,998 (0%) | 0% | 325 | 34,450 | Common Stock |
| Lloyd A. Carney | Director | Sale of securities on an exchange or to another person at price $ 320.70 per share. | 30 Jan 2023 | 1,000 | 4,474 (0%) | 0% | 320.7 | 320,700 | Common Stock |
| Lloyd A. Carney | Director | Sale of securities on an exchange or to another person at price $ 321.84 per share. | 30 Jan 2023 | 324 | 4,150 (0%) | 0% | 321.8 | 104,276 | Common Stock |
| Lloyd A. Carney | Director | Sale of securities on an exchange or to another person at price $ 320.08 per share. | 30 Jan 2023 | 1,376 | 5,474 (0%) | 0% | 320.1 | 440,430 | Common Stock |
| Yuchun Lee | Director | Sale of securities on an exchange or to another person at price $ 321.31 per share. | 27 Jan 2023 | 379 | 2,925 (0%) | 0% | 321.3 | 121,776 | Common Stock |
| Yuchun Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 1,429 | 0 | - | - | Stock Option (Right to Buy) | |
| Yuchun Lee | Director | Sale of securities on an exchange or to another person at price $ 323.32 per share. | 27 Jan 2023 | 80 | 1,875 (0%) | 0% | 323.3 | 25,866 | Common Stock |
| Yuchun Lee | Director | Sale of securities on an exchange or to another person at price $ 322.20 per share. | 27 Jan 2023 | 970 | 1,955 (0%) | 0% | 322.2 | 312,534 | Common Stock |
| Yuchun Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.14 per share. | 27 Jan 2023 | 1,429 | 3,304 (0%) | 0% | 72.1 | 103,088 | Common Stock |
| Yuchun Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.14 per share. | 25 Jan 2023 | 4,000 | 5,875 (0%) | 0% | 72.1 | 288,560 | Common Stock |
| Yuchun Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2023 | 4,000 | 1,429 | - | - | Stock Option (Right to Buy) | |
| Yuchun Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2023 | 4,000 | 5,429 | - | - | Stock Option (Right to Buy) | |
| Yuchun Lee | Director | Sale of securities on an exchange or to another person at price $ 320.94 per share. | 25 Jan 2023 | 680 | 1,875 (0%) | 0% | 320.9 | 218,239 | Common Stock |
| Yuchun Lee | Director | Sale of securities on an exchange or to another person at price $ 320.25 per share. | 25 Jan 2023 | 400 | 2,555 (0%) | 0% | 320.3 | 128,100 | Common Stock |
| Yuchun Lee | Director | Sale of securities on an exchange or to another person at price $ 319.25 per share. | 25 Jan 2023 | 478 | 2,955 (0%) | 0% | 319.3 | 152,602 | Common Stock |
| Yuchun Lee | Director | Sale of securities on an exchange or to another person at price $ 317.95 per share. | 25 Jan 2023 | 1,000 | 3,433 (0%) | 0% | 318.0 | 317,950 | Common Stock |
| Yuchun Lee | Director | Sale of securities on an exchange or to another person at price $ 316.82 per share. | 25 Jan 2023 | 1,140 | 4,433 (0%) | 0% | 316.8 | 361,175 | Common Stock |